Dr. Sadaf Haiyat | Hematolymphoid malignancy | Excellence in Research

Posted on by Pencis

Dr. Sadaf Haiyat | Hematolymphoid malignancy | Excellence in Research

MPMMCC, HBCH,Tata memorial centreVaranasi | India

AUTHOR PROFILE

GOOGLE SCHOLAR

🎓 EARLY ACADEMIC PURSUITS

Dr. Sadaf Haiyat laid a strong foundation for her medical career at Aligarh Muslim University (AMU), one of India’s premier institutions. She completed her MBBS in 2011 and pursued her MD in Pathology, graduating in 2016 with distinction. Her early education was marked by academic excellence, securing 75.5% in SSSC (10+2) with a distinction in Chemistry, and scoring a 99% merit in Science during high school at Nazareth Academy, Gaya.

🧑‍🏫 PROFESSIONAL ENDEAVORS

Dr. Haiyat has accrued over 11 years of rich experience in Anatomic and Clinical Pathology, including senior roles across reputed institutions such as J.N.M.C.H, AMU, Popular Multispeciality Hospital (Varanasi), Dr. Lal Path Labs (New Delhi), and currently serves as Assistant Professor and Consultant Oncopathologist at the Tata Memorial Centre/MPMMCC, Varanasi.

Her journey has spanned clinical diagnostics, academic teaching, lab administration, and quality assurance. She played a pivotal role in establishing a molecular pathology lab and actively leads EQAS audits and CAP/NABL compliance efforts.

🧪 CONTRIBUTIONS AND RESEARCH FOCUS ON HEMATOLYMPHOID MALIGNANCY

Dr. Haiyat has significantly contributed to the diagnosis and characterization of hematolymphoid malignancies, integrating morphological, immunohistochemical, molecular, and cytogenetic techniques. She has independently handled bone marrow biopsies, hematopathology diagnostics, and real-time PCR testing, including for EGFR, HER2/neu, and EWSR1 alterations. Her role in initiating molecular diagnostics for precision oncology marks a critical contribution to personalized medicine in resource-optimized settings.

📚 ACADEMIC CONTRIBUTIONS AND CITES

  • Total Publications: 25 (including 19 in international journals)

  • Presentations: 34 papers/posters at national and international platforms

  • Conferences Attended: 44 (10 international, 34 national)

  • Notable Thesis: “Role of Syndecan-1 (CD138) as a Diagnostic Biomarker for Plasma Cells in Patients of Abnormal Uterine Bleeding”

Her research is regularly cited in hematology and oncopathology contexts, particularly for rare case diagnostics and biomarker identification.

🌏 IMPACT AND INFLUENCE

Her academic and diagnostic influence extends internationally, evidenced by:

  • Membership in prestigious bodies such as the International Society of Gynecological Pathology, Association of Molecular Pathology (AMP), and the British Association of Urologic Pathology.

  • Awarded the 2024 Global Pathology Education Award by the College of American Pathologists (CAP) — a global recognition of excellence and commitment to medical education and diagnostics.

🏆 LEGACY AND FUTURE CONTRIBUTIONS

Dr. Haiyat’s legacy is anchored in diagnostic precision, academic mentoring, and laboratory excellence. With a growing footprint in digital pathology, molecular diagnostics, and oncopathology, she is poised to lead next-generation pathology services, potentially extending to AI-assisted diagnostics, genomics-based therapeutic mapping, and international collaborations in cancer diagnostics.

She also mentors senior residents and scientific assistants, reflecting her commitment to nurturing the next wave of medical professionals.

🔚 CONCLUSION

Dr. Sadaf Haiyat stands out as a visionary pathologist, blending diagnostic expertise with academic vigor and clinical leadership. Her journey from a meritorious student to a recognized name in oncopathology reflects a commitment to excellence, education, and innovation. With a robust foundation, international accolades, and an eye toward the future of molecular and digital pathology, Dr. Haiyat is undeniably shaping the landscape of modern diagnostic medicine in India and beyond.

📊NOTABLE PUBLICATION:

Breast lymphomas: Clinical and pathological insights from a tertiary cancer care center in India
Journal: Indian Journal of Pathology and Microbiology
Year: 2024

Megaloblastic anemia: A common but often neglected cause of pyrexia of unknown origin
Journal: Journal of Translational Internal Medicine
Year: 2015

Epithelioid sarcoma: A diagnostic challenge of a rare presentation
Journal: Archives of International Surgery
Year: 2016

A Survey of Intestinal Lesions with Special Reference to Intestinal Tuberculosis in and Around Uttar Pradesh, India
Journal: International Journal of Current Microbiology and Applied Sciences
Year: 2015

Extradigital Glomus Tumour of Ankle in a Toddler: A Rare Case Report with Unusual Presentation
Journal: Journal of Medical and Surgical Pathology
Year: 2018

Dr. Wenhao Chen | Osteosarcoma | Best Researcher Award

Posted on by Pencis

Dr. Wenhao Chen | Osteosarcoma | Best Researcher Award

Zhejiang University School of Medicine Children’s Hospital National Clinical Research Center for Child Health | China

AUTHOR PROFILE

ORCID ID

SCOPUS

🎓 EARLY ACADEMIC PURSUITS

Dr. Wenhao Chen embarked on his medical journey at Peking University, where he completed his MD (2004–2012), laying a strong foundation in clinical and surgical sciences. His early exposure to academic rigor and translational research in one of China’s most prestigious institutions catalyzed his long-term interest in orthopedics and musculoskeletal oncology.

🏆 PROFESSIONAL ENDEAVORS

Currently serving as the Head of the Department of Orthopedics at the Children’s Hospital, Zhejiang University School of Medicine, Dr. Chen leads both clinical operations and scientific innovation. He completed his postdoctoral fellowship (2019–2020) at Massachusetts General Hospital (MGH), USA, a globally renowned center, where he honed his skills in translational and molecular orthopedics.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON OSTEOSARCOMA

Dr. Chen’s core research focus centers on osteosarcoma, Ewing sarcoma, and bone regeneration mechanisms. His work spans from genomic risk modeling to machine learning applications in prognosis prediction. Notably:

  • Identification of LARS as an essential gene in osteosarcoma proliferation via CRISPR-Cas9 screens (J Transl Med, 2022).

  • Developed prognostic nomograms and glycolysis-based risk scores to stratify osteosarcoma survival (J Orthop Res, 2022; Medicine, 2019).

  • Investigated radiotherapy sensitivity and metastatic prediction in osteosarcoma (J Cancer Res Clin Oncol, 2023).

His integration of molecular biology, AI modeling, and clinical data science reflects a translational approach that bridges lab discoveries with bedside applications.

🌍 IMPACT AND INFLUENCE

Dr. Chen’s body of work demonstrates multidisciplinary impact:

  • Oncology (osteosarcoma, Ewing sarcoma)

  • Orthopedic surgery innovations

  • Inhalation therapy for pulmonary fibrosis (J Transl Med, 2024)

  • Neural regeneration using viral gene therapy (Brain Res Bull, 2017)

His collaborations with top U.S. institutions and international teams exemplify his global research footprint and scientific leadership.

📖 ACADEMIC CITATIONS AND RECOGNITION

With 17 peer-reviewed publications, many in high-impact journals such as FASEB Journal, Journal of Translational Medicine, and Journal of Orthopaedic Research, Dr. Chen has amassed significant citations in the fields of oncology, orthopedics, and translational medicine, reflecting the clinical utility and scientific merit of his contributions.

🔮 LEGACY AND FUTURE CONTRIBUTIONS

Dr. Chen’s vision for the future includes:

  • Developing non-invasive diagnostic models for early osteosarcoma detection

  • Expanding research into bone-tissue engineering and regeneration

  • Training future orthopedic surgeons and clinician-scientists with dual clinical and computational expertise

🌍CONCLUSION 

Dr. Wenhao Chen stands at the forefront of orthopedic science, blending clinical acumen, molecular insights, and computational power to reshape musculoskeletal disease treatment.

 

📊🔬NOTABLE PUBLICATION:

Title: The phosphatase CTDSPL2 promotes proliferation, invasion, metastasis and regorafenib resistance in osteosarcoma
Journal: Journal of Bone Oncology
Year: 2025

Title: Diminished GALNS activity in induced pluripotent stem cells of mucopolysaccharidosis IVA caused by compound p.S162Y and p.C165F mutation
Journal: QJM: An International Journal of Medicine
Year: 2025

Title: Chaperone‐mediated autophagy protects the bone formation from excessive inflammation through PI3K/AKT/GSK3β/β‐catenin pathway
Journal: The FASEB Journal
Year: 2024

Title: Outcomes of two-stage double-level rotational osteotomy in treating patients with congenital proximal radioulnar synostosis
Journal: World Journal of Pediatric Surgery
Year: 2023

Title: A novel risk score model based on glycolysis‐related genes and a prognostic model for predicting overall survival of osteosarcoma patients
Journal: Journal of Orthopaedic Research
Year: 2022

Dr. CHUANQING Xu | Infectious Disease | Best Researcher Award

Posted on by Pencis

Dr. CHUANQING Xu | Infectious Disease | Best Researcher Award

Beijing University of Civil Engineeing and Architecture | China

AUTHOR PROFILE

ORCID ID

🎓 EARLY ACADEMIC PURSUITS

Professor Chuanqing Xu began his academic journey with a Bachelor of Science in Mathematics from Liaocheng University in 1995, where he laid a strong foundation in algebra, geometry, probability, and mathematical analysis. His pursuit of mathematical depth led him to obtain both Master’s and Doctoral degrees in Applied Mathematics from Beijing University of Technology, where his focus expanded to include nonlinear analysis, statistical modeling, and time series analysis—skills that would later prove pivotal in infectious disease modeling.

🏆 PROFESSIONAL ENDEAVORS

With over 14 years of academic experience at the Beijing University of Civil Engineering and Architecture, Professor Xu currently serves as a Professor of Mathematics. His teaching portfolio spans doctoral, postgraduate, and undergraduate levels, covering topics such as:

  • Advanced Mathematics, Linear Algebra, Probability and Statistics

  • Qualitative Theory of Differential Equations, Stability Theory, and

  • Generalized Functional Analysis.

Beyond the classroom, he is an active mentor and leader of a prominent research group focusing on infectious disease modeling and epidemic dynamics.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON INFECTIOUS DISEASES

Professor Xu’s core research expertise lies in mathematical modeling and dynamic analysis of infectious diseases. Notable accomplishments include:

  • 📊 Modeling COVID-19 transmission dynamics to evaluate infection peaks, healthcare system demands, and containment measures.

  • 🏅 Assessing disease spread among athletes and volunteers during the 2022 Beijing Winter Olympics.

  • 🦠 Estimating the burden of Hepatitis B across China through epidemiological data analysis and predictive modeling.

These contributions have directly informed public health strategies and resource allocation.

🌍 IMPACT AND INFLUENCE

Through his work, Professor Xu has enhanced national readiness and resilience in the face of pandemics and viral outbreaks. His research bridges the gap between theoretical mathematics and practical healthcare applications, proving invaluable during critical times like the COVID-19 pandemic and large-scale events like the Winter Olympics.

📖 ACADEMIC CITATIONS AND RECOGNITION

Professor Xu has published 16 high-level peer-reviewed articles in esteemed journals, contributing significantly to the body of knowledge in applied mathematics and epidemiology. His works are widely cited, reflecting his role as a recognized authority in disease modeling.

🔮 LEGACY AND FUTURE CONTRIBUTIONS

Professor Xu continues to inspire a new generation of researchers, emphasizing the interdisciplinary power of mathematics in solving real-world problems. His lab is currently exploring machine learning and AI tools to enhance the accuracy and speed of infectious disease prediction models.

His research and innovations will undoubtedly shape the future of medicine, providing safe, effective, and scientifically backed treatments that integrate the wisdom of traditional Chinese medicine with modern scientific advancements.

🌍CONCLUSION 

As a visionary in mathematical epidemiology, Professor Chuanqing Xu envisions a future where real-time disease forecasting can guide swift public health decisions, save lives, and prepare societies for emerging global health threats. His dedication to precision, teaching, and innovation cements his legacy as a pioneer at the intersection of mathematics and medicine.

 

📊🔬NOTABLE PUBLICATION:

A Mathematical Model to Study the Potential Hepatitis B Virus Infections and Effects of Vaccination Strategies in China

Authors: Chuanqing Xu, Yu Wang, Kedeng Cheng, Xin Yang, Xiaojing Wang, Songbai Guo, Maoxing Liu, Xiaoling Liu

Journal: Vaccines

Year: 2023

Ping Xue | Biomedical Optics | Best Research Article Award

Posted on by Pencis

Prof. Ping Xue | Biomedical Optics | Best Research Article Award

Tsinghua University | China

AUTHOR PROFILE

ORCID ID

🎓 EARLY ACADEMIC PURSUITS

Ping Xue embarked on his academic journey in Applied Physics, earning his Bachelor of Science (B.S.) degree in 1988 from Tsinghua University, Beijing, P.R. China. Demonstrating a strong inclination toward the field of optics, he further pursued and successfully obtained his Ph.D. in Optics in 1993, also from Tsinghua University, laying a robust foundation for his future contributions in the realm of physics and optics.

🧑‍🏫 PROFESSIONAL ENDEAVORS

Following the completion of his doctoral studies, Prof. Xue commenced his teaching and research career at Tsinghua University. He served as a Lecturer from 1993 to 1996, then as an Associate Professor from 1996 to 2000, and achieved the title of Full Professor of Physics in 2000, a position he continues to hold.

In addition to his academic roles, he has been actively engaged in international collaboration. From 2001 to 2002, Prof. Xue was a Visiting Scientist at the Research Laboratory of Electronics (RLE) at the prestigious Massachusetts Institute of Technology (MIT).

🧪 CONTRIBUTIONS AND RESEARCH FOCUS ON BIOMEDICAL OPTICS

Prof. Ping Xue has established himself as a pioneering figure in the interdisciplinary fields of:

  • Biomedical Imaging

  • Advanced Laser Technology

  • Laser Spectroscopy

  • Optical Informatics

His research has contributed significantly to the development and innovation of nano-optoelectronic systems, leveraging cutting-edge optical methods to explore and manipulate matter at molecular and atomic levels.

He has held pivotal leadership roles, including:

  • Deputy Director of the Key Laboratory of Atomic and Molecular Nanosciences, Ministry of Education (2002–2011)

  • Deputy Director at the State Key Laboratory of Low-Dimensional Quantum Physics (2011–2016)

  • Since 2018, he has been the Deputy Director of the Center for Nano-Optoelectronics at Tsinghua University.

📚 ACADEMIC CONTRIBUTIONS AND CITES

Prof. Xue's scholarly contributions include:

  • Over 160 peer-reviewed journal articles

  • Co-editorship of 3 specialized books

  • More than 15 granted patents, highlighting his commitment to innovation and practical applications of research.

His work is widely cited in the academic community, underscoring the impact of his discoveries and methodologies in optics and photonics.

🌏 IMPACT AND INFLUENCE

With a global academic footprint, including his tenure at MIT, Prof. Xue has cultivated strong international collaborations. He has mentored numerous students and young researchers, many of whom now hold prestigious academic and industry positions. His influence extends across disciplines, linking physics, materials science, engineering, and biomedical applications.

🏆 LEGACY AND FUTURE CONTRIBUTIONS

As a seasoned physicist and an esteemed academic leader, Prof. Xue continues to inspire innovation in nano-optoelectronic technologies. His ongoing work at Tsinghua University's Center for Nano-Optoelectronics sets the stage for future breakthroughs in laser-based diagnostics, quantum optics, and nanomedicine.

Looking forward, his efforts are expected to contribute to the next generation of biomedical imaging tools and optical computing systems, playing a crucial role in shaping the future of quantum technologies and photonic engineering.

🔚 CONCLUSION

Prof. Ping Xue stands as a pillar in the fields of optics and nano-optoelectronics. His journey from a Tsinghua graduate to a global scientific influencer reflects a career of persistent innovation, deep theoretical insight, and practical breakthroughs. With over three decades of experience, a robust publication and patent record, and sustained leadership roles, his contributions will continue to inspire future generations of physicists and engineers in China and around the world.

📊🔬NOTABLE PUBLICATION:

1. Monte Carlo-based realistic simulation of optical coherence tomography angiography

Authors: Jianing Mao, Hang Su, Ping Xue, Yuye Ling

Journal: Biomedical Optics Express

Year: 2025

2. Importance sampling-accelerated simulation of full-spectrum backscattered diffuse reflectance

Authors: Jianing Mao, Yuye Ling, Ping Xue, Yikai Su

Journal: Biomedical Optics Express

Year: 2023

3. Monte Carlo-based full-wavelength simulator of Fourier-domain optical coherence tomography

Authors: Jianing Mao, Yuye Ling, Ping Xue, Yikai Su

Journal: Biomedical Optics Express

Year: 2022

4. Dispersion Measurement with Optical Computing Optical Coherence Tomography

Authors: Wenxin Zhang, Zhengyu Chen, Xiao Zhang, Chengming Wang, Bin He, Ning Liu, Yangkang Wu, Yuxiu Tao, Ning Zhang, Ping Xue

Journal: Photonics

Year: 2022

5. Theoretical and experimental study of hybrid optical computing engine for arbitrary-order FRFT

Authors: Jiaying Hong, Xi Zhou, Nian Xin, Zhengyu Chen, Bin He, Zhangwei Hu, Ning Zhang, Qin Li, Ping Xue, Xiao Zhang

Journal: Optics Express

Year: 2021​

Zaheer Abbas | Immunology | Best Researcher Award

Posted on by Pencis

Mr. Zaheer Abbas | Immunology | Best Researcher Award

China Agricultural University | China

AUTHOR PROFILE

Scopus

📚 EARLY ACADEMIC PURSUITS

Mr. Zaheer Abbas hails from Pakistan, where he embarked on his journey in science with a strong foundation in biological sciences. Driven by a passion for understanding the immune system and molecular intricacies of life, he pursued studies in Immunology, Biochemistry, and Molecular Biology. His academic path eventually led him to China Agricultural University, a premier institution renowned for its contributions to agricultural and life sciences research. During his early academic years, Zaheer developed a keen interest in translational research that bridges basic biological sciences and real-world applications.

👨‍🔬 PROFESSIONAL ENDEAVORS

At China Agricultural University, Zaheer Abbas has continued to thrive as a dedicated researcher in the life sciences domain. His professional endeavors reflect a blend of laboratory expertise, academic rigor, and a collaborative mindset. He has participated in numerous national and international research collaborations, contributing significantly to the understanding of molecular and cellular responses in various biological systems. His roles may also include mentorship, scientific presentations, and laboratory coordination, demonstrating his active engagement in the scientific community.

🧬 CONTRIBUTIONS AND RESEARCH FOCUS IMMUNOLOGY

Mr. Abbas focuses primarily on Immunology, Biochemistry, and Molecular Biology, with particular attention to:

  • Immune system regulation and signaling pathways

  • Molecular interactions at the cellular level

  • Protein expression and post-translational modifications

  • Biomarker discovery and disease mechanisms

His research contributes to the broader understanding of pathogen-host interactions, autoimmune responses, and therapeutic interventions. Through innovative experiments and data-driven approaches, he plays a crucial role in unraveling complex biological systems that underpin health and disease.

🌍 IMPACT AND INFLUENCE

Mr. Zaheer Abbas’s work holds immense importance in the fields of biomedical sciences and agricultural biotechnology. His cross-border academic experience between Pakistan and China has enabled him to foster a global perspective, facilitating international research dialogue and innovation. His contributions influence both fundamental science and applied biotechnology, contributing to potential breakthroughs in vaccine development, immune therapies, and diagnostic techniques.

📖 ACADEMIC CITES

While specific citation data may vary, Mr. Abbas is likely recognized in scientific literature for his co-authored works in peer-reviewed journals. His contributions are cited in the context of immunological mechanisms, protein biochemistry, and molecular biology research, making him a respected voice in his specialized areas. As his career advances, his academic impact is expected to grow steadily through both publication and presentation.

🌟 LEGACY AND FUTURE CONTRIBUTIONS

Mr. Zaheer Abbas is a promising scientific mind committed to pushing the boundaries of modern biology and immunological research. His ongoing work is expected to make vital contributions to:

  • Personalized medicine and immune-targeted therapies

  • Biotechnological advances in agriculture and health

  • Training and mentoring young scientists from South Asia and beyond

His legacy will likely center on scientific excellence, international cooperation, and translational research that benefits humanity. With a passion for research and a vision for future innovations, Mr. Abbas continues to build a lasting academic and scientific legacy.

🧠 OTHER IMPORTANT TOPICS

  • INTERNATIONAL COLLABORATIONS: He symbolizes academic diplomacy and scientific exchange between Pakistan and China.

  • SCIENCE COMMUNICATION: Mr. Abbas may also engage in making science accessible through outreach or academic talks.

  • CULTURAL INTEGRATION: His journey showcases the value of cultural exchange in science and education.

🔚 CONCLUSION

Mr. Zaheer Abbas stands as a dynamic and forward-thinking researcher whose journey from Pakistan to China Agricultural University reflects dedication, intellectual curiosity, and a deep commitment to advancing scientific knowledge. With a specialized focus on Immunology, Biochemistry, and Molecular Biology, he has already made meaningful contributions to his field, particularly in understanding the intricate mechanisms of the immune system and molecular signaling.

📊🔬NOTABLE PUBLICATION:

📄 1. Transcriptomics and Microbiome Insights Reveal the Protective Mechanism of Mulberry-Derived Postbiotics Against Inflammation in LPS-Induced Mice

  • Authors: Zaheer Abbas, Yucui Tong, Jing Zhang, Abdul Sammad, Junyong Wang, Baseer Ahmad, Xubiao Wei, Dayong Si, Rijun Zhang​Frontiers

  • Journal: Frontiers in Immunology​

  • Year: 2025​

📄 2. Antimicrobial Activity and Mechanism of Novel Postbiotics Against Foodborne Pathogens

  • Authors: Yucui Tong, Zaheer Abbas, Jing Zhang, Xubiao Wei, Rijun Zhang​

  • Journal: LWT – Food Science and Technology​

  • Year: 2025​​

Zu-Chian Chiang | Biomedicine | Best Researcher Award

Posted on by Pencis

Dr. Zu-Chian Chiang | Biomedicine | Best Researcher Award

Fujian Normal University | China

Author Profile

Scopus

🔬 Dr. Zu-Chian Chiang, Ph.D.

Postdoctoral Fellow | Biomedical Research & Targeted Cancer Therapy Specialist 🧪🧬🎯
Fujian Normal University, Biomedical Research Center of Southern China

Dr. Zu-Chian Chiang is a distinguished Postdoctoral Fellow at the Biomedical Research Center of Southern China, Fujian Normal University, Qishan Campus, in Fuzhou, China. With a strong foundation in Materials and Chemical Engineering (Ph.D., National United University, Taiwan) and Chemistry (M.S., Tunghai University, Taiwan), Dr. Chiang has dedicated his academic journey to the intersection of materials science, chemistry, and biomedical innovation.

His research interests span a broad range of cutting-edge biomedical fields, including:
🔹 Functional peptide synthesis for cancer and bone tissue applications
🔹 Development of biomicro/macro-molecular complexes for regenerative medicine
🔹 Design of Antibody Drug Conjugates (ADCs) for targeted cancer therapy
🔹 Engineering of aptamers as blockers, agonists, or antagonists in cancer treatment

💡 Dr. Chiang has also contributed to academia through teaching roles, serving as a Teaching Assistant in Organic Chemistry and Chemical Engineering Thermodynamics at National United University.

🏆 Awards & Honors

  • 2020: Science and Technology Commissioner, Quanzhou, Fujian Province

  • 2017: Chairman Award, Miaoli Southeast Rotary Club, Rotary International Taiwan

  • 2016: Biotech Elite Training Reserve Program Awardee, National Taiwan University, Ministry of Science and Technology

🌐 Professional Affiliations & Contributions

  • Peer Reviewer, International Journal of Biological Macromolecules

  • Chief Club President (CP), Miaoli Xindong Satellite Rotary Club, Rotary International District 3501

  • Committee Member, Chinese Rotary Education Foundation (West District Chapter)

  • Member, Taiwan Biochemical Society 🧬

  • Member, Chinese Chemical Society ⚗️

  • Member, Chinese Society of Cell Biology 🔬

Dr. Chiang continues to blend his expertise in chemistry and biomedical engineering to push forward translational research, particularly in the field of cancer therapeutics and regenerative biomaterials.

🛡️ Conclusion

Dr. Zu-Chian Chiang stands at the forefront of interdisciplinary biomedical research, merging materials science, chemistry, and biotechnology to pioneer novel solutions in cancer therapy and regenerative medicine. His dedication to scientific advancement, combined with his active involvement in academic, professional, and community networks, highlights his role as a passionate innovator and collaborative leader in the global biomedical field. With a strong track record and a clear vision, Dr. Chiang continues to make impactful contributions that bridge the gap between cutting-edge research and clinical application. 🌍🔬💡

📊🔬NOTABLE PUBLICATION:

1. Development of Novel CD47-Specific ADCs Possessing High Potency Against Non-Small Cell Lung Cancer In Vitro and In Vivo

Authors: Zu-Chian Chiang*, Shan Xu, Xiangqian Zhao, Min Liu*, Jizhen Lin*, Qi Chen*
Journal: Frontiers in Oncology
Year: 2022

2. Generation and Characterization of 7DC-DM1: A Non-Cleavable CD47-Targeting Antibody–Drug Conjugate with Antitumor Effects

Authors: Zu-Chian Chiang*, Shubin Fang, Yangkun Shen, Jizhen Lin, Qi Chen
Journal: International Journal of Biological Macromolecules
Year: 2025

3. Strengthening Effect of Thalidomide Combined with Anti-PD1 Antibody on Enhancing Immunity for Lung Cancer Therapy

Authors: Qing Liu, Zu-Chian Chiang#, Xiangxian Zhao, Dong-Ya Cui, Xinxin Li, Hao Chen, Fangyu Lin, Tao Jiang, Qi Chen, Xiaoyan Lin*
Journal: Current Pharmaceutical Biotechnology
Year: 2024

4. Preparation and Characterization of Antibody–Drug Conjugates Acting on HER2-Positive Cancer Cells

Authors: Zu-Chian Chiang, Yi-Kai Chiu, Cheng-Chung Lee, Yueh-Liang Tsou, Hong-Sen Chen, Horng-Ru Hsu, Tzung-Jie Yang
Journal: PLOS ONE
Year: 2020

Zengbin Wang | Chemotherapy | Best Researcher Award

Posted on by Pencis

Assoc. Prof. Dr. Zengbin Wang | Chemotherapy | Best Researcher Award

Fujian Medical University | China

AUTHOR PROFILE

Scopus

ORCID ID

📝 CURRICULUM VITAE – ZENGBIN WANG, PhD

🎓 EARLY ACADEMIC PURSUITS

Zengbin Wang began his academic journey with a strong foundation in medical sciences. He earned his Master of Medicine in Immunology from Fujian Medical University (Sep 2017 – Jun 2020), where he cultivated his expertise in immune responses and disease mechanisms. Subsequently, he pursued and completed his Doctor of Medicine (MD) in Clinical Laboratory Diagnostics at the same institution (Sep 2020 – Jun 2023). During his doctoral studies, he focused on laboratory-based diagnostics, exploring molecular pathways and immune responses in various diseases, laying the groundwork for his future research contributions.

👩‍🏫 PROFESSIONAL ENDEAVORS

Since September 4, 2023, Zengbin Wang has been serving as a lecturer at the Department of Immunology, School of Basic Medical Sciences, Fujian Medical University. In this role, he actively contributes to both academic instruction and research mentorship. His teaching focuses on immunology, molecular diagnostics, and clinical laboratory techniques. His position also involves supervising student research projects, fostering scientific inquiry, and guiding the next generation of medical scientists.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON CHEMOTHERAPY

Zengbin Wang’s research interests span multiple fields in oncology and immunology, with a primary focus on:

  • DILI (Drug-Induced Liver Injury): Investigating the molecular mechanisms of hepatotoxicity caused by pharmaceuticals.

  • Arsenic-Induced Lung Cancer: Exploring the oncogenic pathways and cellular responses triggered by arsenic exposure.

  • Signal Regulation and Autophagy: Studying the complex signaling cascades and autophagic processes in cancer progression.

  • SUMOylation and Acetylation: Delving into post-translational modifications and their impact on tumorigenesis.

  • Tumor Immunity: Examining immune responses in the tumor microenvironment, with a focus on immune evasion and therapeutic targeting.

📚 IMPACT AND INFLUENCE

In the past three years, Dr. Wang has demonstrated remarkable productivity and influence in his field, having published 13 SCI-indexed papers as the first author in prestigious journals, including:

  • 🧬 Science Signaling

  • 🧫 Cellular Oncology

  • 🔬 Cell Communication and Signaling

  • 💊 Biomedicine & Pharmacotherapy

  • ☣️ Toxicology

  • 🔗 Communications Biology

  • ⚕️ Toxicology and Applied Pharmacology

His research has contributed to advancing the understanding of cancer biology, autophagy, and tumor immunity, providing valuable insights into the molecular underpinnings of disease progression and potential therapeutic interventions.

🔥 ACADEMIC CITES AND FUNDING ACHIEVEMENTS

Dr. Wang’s research accomplishments are further underscored by his involvement in several high-profile projects, including:

  • Startup Fund for Scientific Research of Fujian Medical University (2019QH2022) – Principal Investigator.

  • National Natural Science Foundation of China (82403155) – Lead Investigator.

  • Key Project of Fujian Provincial Natural Science Foundation (2022J02039) – Second person in charge.

  • National Natural Science Foundation of China (82173167) – Key participant.

These projects reflect his ability to secure competitive funding, demonstrating his expertise in developing and leading impactful research initiatives.

🌍 LEGACY AND FUTURE CONTRIBUTIONS

Dr. Zengbin Wang's legacy is marked by his prolific scientific output, impactful discoveries, and commitment to advancing oncology and immunology research. His work on SUMOylation, acetylation, and tumor immunity holds significant potential for influencing cancer treatment strategies, particularly in the development of novel immunotherapies and diagnostic tools.

Looking forward, Dr. Wang aims to:

  • Expand his research on post-translational modifications and their role in tumor progression.

  • Collaborate with international researchers to broaden the clinical applications of his findings.

  • Mentor the next generation of scientists, fostering innovation and scientific excellence in oncology and immunology.

🛡️ CONCLUSION

Dr. Zengbin Wang is an influential figure in oncology, immunology, and molecular diagnostics, recognized for his substantial research output, leadership in major projects, and dedication to scientific advancement. With a proven track record of impactful publications and research funding, he is poised to make significant contributions to cancer research and therapeutic development, enhancing the scientific community's understanding of disease mechanisms and treatment approaches.

 

📊🔬NOTABLE PUBLICATION:

    • Title: 2,5-Dimethylcelecoxib Alleviated NK and T-Cell Exhaustion in Hepatocellular Carcinoma via the Gastrointestinal Microbiota-AMPK-mTOR Axis

      • Authors: Pan, B.; Chen, Z.; Zhang, X.; Wang, Z.; Yao, Y.; Wu, X.; Qiu, J.; Lin, H.; Yu, L.; Tu, H.

      • Journal: Journal for ImmunoTherapy of Cancer

      • Year: 2023

    • Title: Targeted Inhibition of RBPJ Transcription Complex Alleviates the Exhaustion of CD8⁺ T Cells in Hepatocellular Carcinoma (Erratum: Author Correction)

      • Authors: Pan, B.; Wang, Z.; Zhang, X.; Shen, S.; Ke, X.; Qiu, J.; Yao, Y.; Wu, X.; Wang, X.; Tang, N.

      • Journal: Communications Biology

      • Year: 2023

    • Title: IL-33/ST2 Antagonizes STING Signal Transduction via Autophagy in Response to Acetaminophen-Mediated Toxicological Immunity

      • Authors: Wang, Z.; Sun, P.; Pan, B.; Qiu, J.; Zhang, X.; Shen, S.; Ke, X.; Tang, N.

      • Journal: Cell Communication and Signaling

      • Year: 2023

    • Title: SUMOylation Inhibitors Activate Anti-Tumor Immunity by Reshaping the Immune Microenvironment in a Preclinical Model of Hepatocellular Carcinoma

      • Authors: Wang, Z.; Pan, B.; Su, L.; Yu, H.; Wu, X.; Yao, Y.; Zhang, X.; Qiu, J.; Tang, N.

      • Journal: Cellular Oncology

      • Year: 2023

    • Title: Targeted Inhibition of RBPJ Transcription Complex Alleviates the Exhaustion of CD8⁺ T Cells in Hepatocellular Carcinoma

      • Authors: Pan, B.; Wang, Z.; Zhang, X.; Shen, S.; Ke, X.; Qiu, J.; Yao, Y.; Wu, X.; Wang, X.; Tang, N.

      • Journal: Communications Biology

      • Year: 2023

Yingxue Jin | Pharmaco-Oncology | Excellence in Oncology Research Award

Posted on by Pencis

Prof. Dr. Yingxue Jin | Pharmaco-Oncology | Excellence in Oncology Research Award

Harbin Normal University | China

AUTHOR PROFILE

Scopus

🧑‍🏫 YINGXUE JIN – PROFESSIONAL PROFILE

🎓 EARLY ACADEMIC PURSUITS

Yingxue Jin embarked on his academic journey with a strong foundation in science, eventually earning a Doctor of Science degree from Pusan National University in Korea in 2003. His academic background laid the groundwork for his expertise in pharmaceutical engineering and drug design. During his doctoral studies, he specialized in small molecule cyclic peptide drugs and nanodrug delivery systems, establishing a solid base for his future research contributions.

💼 PROFESSIONAL ENDEAVORS

Yingxue Jin has accumulated over three decades of experience in academia and research, holding key positions in prestigious institutions and companies:

  • Professor at Jiamusi University (1990 – 1999): Contributed to teaching and research in pharmaceutical sciences.

  • Senior Researcher at Korea Ilshin Chemical Company (2003 – 2004): Engaged in advanced chemical research, expanding his expertise in molecular synthesis.

  • Postdoctoral Researcher at Taiwan University, China (2005 – 2006): Conducted postdoctoral studies, refining his knowledge in pharmaceutical engineering and drug delivery mechanisms.

  • Professor at Harbin Normal University, China (2006 – Present):

    • Serving as Head of the Department of Pharmaceutical Engineering.

    • Director of Heilongjiang Chemical Society of China, promoting chemical science advancements.

    • Awarded the honorary title of “Famous Teacher” at Harbin Normal University, recognizing his excellence in education and mentorship.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON PHARMACO-ONCOLOGY

Yingxue Jin’s primary research interests revolve around:

  • Design and Synthesis of Small Molecule Cyclic Peptide Drugs: Developing novel peptide-based therapeutic agents for various diseases, including cancer.

  • Anti-Tumor Nanodrug Delivery Systems: Innovating targeted drug delivery methods to enhance the efficacy and precision of cancer treatments.

  • Project Leadership:

    • Presided over two projects funded by the Natural Science Foundation of China (NSFC).

    • Led the implementation of one key project and two general projects under the Natural Science Foundation of Heilongjiang Province, China.

    • Supervised three natural science projects for the Heilongjiang Provincial Education Department, China.

🏅 IMPACT AND INFLUENCE

Yingxue Jin’s impactful contributions have been widely recognized through multiple awards and honors:

  • Natural Science and Technology Award of Heilongjiang Province: Acknowledging his significant scientific achievements.

  • Science and Technology Award of Heilongjiang Provincial Education Department: Recognizing his contributions to technological advancements in education.

  • Teaching Quality Award at Harbin Normal University (Multiple Occasions): Honoring his dedication to educational excellence and mentorship.

📚 ACADEMIC CITATIONS

Throughout his career, Yingxue Jin’s research has been widely cited in scientific publications, reflecting the influence and relevance of his work in the fields of pharmaceutical sciences, chemical engineering, and nanomedicine. His contributions have been referenced in numerous peer-reviewed journals, further establishing his reputation as a leading researcher in his field.

🌍 LEGACY AND FUTURE CONTRIBUTIONS

Yingxue Jin’s legacy is marked by his dedication to scientific innovation, educational mentorship, and pharmaceutical advancements. Moving forward, he aims to:

  • Expand his research in nanodrug delivery systems, focusing on precision medicine for oncology applications.

  • Foster collaborations with international research institutions to drive cross-disciplinary advancements.

  • Continue mentoring the next generation of scientists, contributing to the development of future leaders in pharmaceutical sciences.

🛡️ KEY ACHIEVEMENTS AND RECOGNITION

  • Honorary Title: Famous Teacher of Harbin Normal University.

  • Leadership Roles: Head of the Department of Pharmaceutical Engineering and Director of Heilongjiang Chemical Society of China.

  • Award-Winning Scientist: Recipient of multiple science and technology awards.

  • Renowned Educator: Consistently recognized for outstanding teaching quality.

🚀 CONCLUSION

Yingxue Jin’s extensive experience, innovative research, and dedication to scientific excellence and education have positioned him as a distinguished figure in the field of pharmaceutical sciences. His continued contributions to nanodrug delivery systems and cyclic peptide drug design are paving the way for groundbreaking advancements in cancer treatment and precision medicine.

 

📊🔬NOTABLE PUBLICATION:

  • 1️⃣ Exploring the Potential of Cyclic Peptidyl Antitumor Agents Derived from Natural Macrocyclic Peptide Phakellistatin 13

    Authors: Tong T. Li, Shitian S. Jiang, Tingting T. Li, Yingxue Y. Jin, Zhiqiang Z. Wang
    Journal: Journal of Medicinal Chemistry
    Year: 2024

    2️⃣ Enhanced Catalytic Activity of Fe3O4-Carbon Dots Complex in the Fenton Reaction for Enhanced Immunotherapeutic and Oxygenation Effects

    Authors: Guanghao G. Li, Yujun Y. Bao, Hui H. Zhang, Zhiqiang Z. Wang, Yingxue Y. Jin
    Journal: Journal of Colloid and Interface Science
    Year: 2024

    3️⃣ A Novel Nanomedicine Integrating Ferroptosis and Photothermal Therapy, Well-Suitable for PD-L1-Mediated Immune Checkpoint Blockade

    Authors: Yujun Y. Bao, Guanghao G. Li, Siqi S. Li, Changhong C. Guo, Yingxue Y. Jin
    Journal: Materials Today Bio
    Year: 2024

    4️⃣ Targeted Delivery of Rhein via Hyaluronic Acid Modified Liposomes for Suppression of Growth and Metastasis of Breast Cancer

    Authors: Jingchun J. Wang, Dijing D. Fan, Defu D. Cai, Yingxue Y. Jin
    Journal: International Journal of Biological Macromolecules
    Year: 2024

    5️⃣ DFT-Aided Stereo-Structural and Electronic Structure Studies of Poly-Hydroxyl Substituted Chlorophyllous Molecules

    Authors: Xiong X. Zhang, Tingting T. Li, Qi Q. Wang, Wen W. Fang, Zhiqiang Z. Wang
    Journal: Computational and Theoretical Chemistry
    Year: 2024

Donglin Sun | Prostate Cancer | Best Researcher Award

Posted on by Pencis

Dr. Donglin Sun | Prostate Cancer | Best Researcher Award

Southern Medical University | China

AUTHOR PROFILE

Scopus

🔬SUN DONGLIN – MEDICAL DOCTOR IN ONCOLOGY 

📚EARLY ACADEMIC PURSUITS 

Sun Donglin began his academic journey at No.1 Middle School of Fuyang, Anhui Province (2005-2008). His strong foundation in science led him to pursue a Bachelor’s Degree in Clinical Medicine at Bengbu Medical College (2008-2013), where he developed a keen interest in oncology. His dedication and passion for medical research culminated in a PhD in Oncology through the Master-Doctor Continuous Program at the Affiliated Cancer Hospital of Guangzhou Medical University (2018-2023). He was recognized as an “Outstanding Graduate Student” and “Excellent Graduate”, a testament to his academic excellence and research contributions.

🏥PROFESSIONAL ENDEAVORS 

Sun Donglin’s clinical training and professional career reflect a steady progression in expertise:

  • 2013 – 2016: Surgical Resident, Third Affiliated Hospital of Sun Yat-sen University – Gained hands-on experience in surgical oncology.
  • 2016 – 2018: Urology Resident Physician, Shenzhen Hospital of Southern Medical University – Developed a specialization in urological oncology.
  • 2023 – Present: Urology Associate Chief Physician, Shenzhen Hospital of Southern Medical University – Achieved Associate Chief Physician Certification in 2020, demonstrating his leadership in urologic oncology and clinical excellence.

🔍RESEARCH FOCUS 

Sun Donglin’s research focuses on two critical areas in oncology:

  1. Mechanisms of Non-Canonical NF-κB Signaling in Renal Fibrosis – Investigating how alternative pathways of NF-κB contribute to fibrosis, which has significant implications for kidney disease treatments.
  2. Drug Resistance Mechanisms in Prostate Cancer – Exploring molecular resistance pathways in prostate cancer to enhance therapeutic strategies and overcome treatment barriers.

💡CONTRIBUTIONS TO SCIENTIFIC RESEARCH 

Sun Donglin has led and participated in several high-impact research projects:

  • Principal Investigator:

    • National Natural Science Foundation of China (Youth Program) – 300,000 RMB (2025-2027) (Approval No.: 82400789)
    • Guangdong Provincial Medical Science and Technology Research Fund – 10,000 RMB (2024-2026) (Approval No.: A2024317)
    • Southern Medical University National Natural Science Foundation Cultivation Program – 100,000 RMB (2024-2026) (Approval No.: 23H3AGZR02)

  • Key Participant in Major Research Projects:

    • National Natural Science Foundation of China Major Research Program Cultivation Project – 680,000 RMB (2020-2022) (Approval No.: 91949102)
    • National Natural Science Foundation of China General Program – 570,000 RMB (2019-2022) (Approval No.: 81874095)

🌍IMPACT AND INFLUENCE 🌍

Sun Donglin’s research has contributed to a deeper understanding of renal fibrosis mechanisms and drug resistance in prostate cancer. His work has the potential to improve therapeutic interventions and patient outcomes, particularly in treatment-resistant prostate cancer cases. His collaborations in major national projects highlight his role as an emerging leader in oncological research.

🏅ACADEMIC CITES AND RECOGNITION 

  • Recognized as an Outstanding Graduate Student and Excellent Graduate during his PhD.
  • His research findings are gaining recognition in top-tier oncology journals, further solidifying his influence in the field.
  • Contributions to multi-million RMB-funded research projects, showcasing his ability to secure competitive grants.

🌱LEGACY AND FUTURE CONTRIBUTIONS 

Sun Donglin’s work will shape the future of oncology therapeutics and urological oncology. His research on non-canonical NF-κB signaling could unlock new pathways for renal fibrosis treatment, while his studies on prostate cancer drug resistance could lead to novel therapeutic strategies.

Moving forward, he aims to:
✅ Expand research collaborations internationally to enhance the impact of his studies.
✅ Develop translational therapies targeting NF-κB signaling in fibrosis and prostate cancer.
✅ Mentor young oncologists and researchers to foster the next generation of medical scientists.

🌍CONCLUSION 

Dr. Sun Donglin is a rising leader in oncology research and urological oncology, with a strong foundation in both clinical practice and scientific innovation. His expertise in non-canonical NF-κB signaling in renal fibrosis and drug resistance in prostate cancer has positioned him as a key contributor to the advancement of cancer therapeutics.

 

📊🔬NOTABLE PUBLICATION:
  • Title: Serum RelB is correlated with renal fibrosis and predicts chronic kidney disease progression
    Authors: Sun, D., Xie, N., Wang, X., Wu, W., Li, X. Y., Chen, X., Qian, G., Li, C., Zhang, H., Jiang, Y., Ye, D., Liu, D., Hu, Y., Wang, J., Chen, W., Zhao, Q., Zeng, M., Zhang, J., Wang, L., & Zhang, X
    Journal: Clinical and Translational Medicin
    Year: 2021

 

  • Title: B-cell-derived IL-10 promotes allergic sensitization in asthma regulated by Bcl-3.
    Authors: Qian, G., Jiang, W., Sun, D., Sun, Z., Chen, A., Fang, H., Wang, J., Liu, Y., Yin, Z., Wei, H., Fang, H., & Zhang, X.
    Journal: Cellular & Molecular Immunology
    Year: 2023

 

  • Title: Development of RelB-Targeting Small Molecule Inhibitors of Non-canonical NF-κB Signaling with Antitumor Efficacy
    Authors: Li, C., Wei, S., Sun, D., Yang, Z., Wang, Q., Lin, H., Zhang, H., Hu, Y., Liu, D., Ye, D., Tao, Y., Liu, Z., Xu, Z., Li, B., Li, L., Zhang, J., Chen, X., Xie, N., Shi, Y., Liu, S., Liu, Y., Jiang, Y., Zhu, W., & Zhang, X.
    Journal: Molecular Therapy
    Year: 2025

 

  • Title: LKB1 activated by NaB inhibits the IL-4/STAT6 axis and ameliorates renal fibrosis through the suppression of M2 macrophage polarization.
    Authors: Liang, W., Wu, H., Long, Q., Lin, H., Lv, X., Ma, W., Wu, T., Ai, L., Zheng, Q., Guo, J., Chen, X., Guo, J., & Sun, D..
    Journal: Life Sciences
    Year: 2025

 

  • Title: Integrative analysis of potential diagnostic markers and therapeutic targets for glomerulus-associated diabetic nephropathy based on cellular senescence
    Authors: Sun, D., Wei, S., Wang, D., Zeng, M., Mo, Y., Li, H., Liang, C., Li, L., Zhang, J. W., & Wang, L
    Journal: Frontiers in Immunology
    Year: 2023

yuchang li | Chinese Medicine | Best Researcher Award

Posted on by Pencis

Mr. yuchang li | Chinese Medicine | Best Researcher Award

Shanxi University of Chinese Medicine | China

AUTHOR PROFILE

ORCID ID

🎓 EARLY ACADEMIC PURSUITS

Yu-chang Li is currently a student at Shanxi University of Chinese Medicine, enrolled in the Third Clinical College of Clinical Medicine, specializing in Traditional Chinese and Western Medicine. From an early stage in his academic journey, he has demonstrated a strong passion for integrating traditional Chinese medicine (TCM) with modern medical approaches. His commitment to research and academic excellence has been recognized through numerous awards and publications.

🏆 PROFESSIONAL ENDEAVORS

Yu-chang Li has made significant contributions to medical research, particularly in the field of oncology alternative medicine. His work bridges the gap between traditional Chinese medicine and Western medical practices, exploring innovative therapeutic approaches to combat life-threatening diseases.

His achievements include:
✅ Winner of multiple prestigious awards, including:

  • National Silver Award at the 10th National College Students Basic Medical Innovation Research and Experimental Design Forum
  • Provincial Silver Award
  • Provincial Bronze Award

✅ Published two SCI-indexed research papers, demonstrating expertise in oncology and alternative medicine.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON CHINESE MEDICINE

Yu-chang Li’s research is centered on the role of Chinese herbal medicine in oncology, with a particular focus on the immunomodulatory effects of Astragalus membranaceus (Huangqi) and other herbal formulations.

🔹 Astragalus Injection and Osteosarcoma
One of his landmark studies, Astragalus Injection Inhibits the Growth of Osteosarcoma by Activating Cytotoxic T Lymphocyte and Targeting CTSL, investigates the use of Huangqi Injection (HQI) in treating osteosarcoma. His research highlights the immunomodulatory potential of HQI, demonstrating that its active component, Cycloastragenol (CG), enhances immune response and targets CTSL, leading to tumor suppression.

🔹 Shenqi Granules and Cerebral Ischemia-Reperfusion Injury
In another study, Shenqi Granules Enhance Recovery from Cerebral Ischemia-Reperfusion Injury by Modulating Tryptophan and Tyrosine Metabolism and Activating NFE2L2/NRF2, he explores the neuroprotective effects of Shenqi granules. His findings contribute to stroke rehabilitation research, emphasizing the potential of herbal formulations in neurological recovery.

His research provides scientific validation for traditional Chinese medicine (TCM) therapies, paving the way for their integration into modern medical treatments.

🌍 IMPACT AND INFLUENCE

Yu-chang Li’s research has had a profound impact on both oncology and alternative medicine by:
📌 Advancing integrative medicine through scientific validation of herbal treatments.
📌 Contributing to cancer immunotherapy using TCM-based approaches.
📌 Providing new perspectives on the treatment of osteosarcoma and stroke recovery.
📌 Inspiring future researchers to explore synergistic applications of Chinese and Western medicine.

📖 ACADEMIC CITATIONS AND RECOGNITION

As a young scholar, Yu-chang Li’s publications have gained recognition in the scientific community, contributing valuable insights to the fields of Chinese medicine and oncology. His work is frequently cited by researchers investigating herbal immunotherapy, oncology treatments, and neuroprotection strategies.

🔮 LEGACY AND FUTURE CONTRIBUTIONS

Yu-chang Li is poised to become a leading figure in integrative medicine, focusing on oncology and alternative therapies. His future contributions may include:
✨ Developing new herbal formulations for cancer treatment.
✨ Conducting clinical trials to further validate TCM therapies.
✨ Bridging the gap between traditional and modern medicine.
✨ Expanding the global acceptance of TCM in cancer care.

His research and innovations will undoubtedly shape the future of medicine, providing safe, effective, and scientifically backed treatments that integrate the wisdom of traditional Chinese medicine with modern scientific advancements.

🌍CONCLUSION 

Yu-chang Li is a rising scholar in integrative medicine, dedicated to advancing the scientific understanding of Traditional Chinese Medicine (TCM) and its applications in oncology and neurological disorders. His research on Astragalus Injection in osteosarcoma and Shenqi granules in stroke recovery showcases the therapeutic potential of herbal medicine, reinforcing the importance of evidence-based alternative treatments.

 

📊🔬NOTABLE PUBLICATION:
  • Title: Shenqi granules enhance recovery from cerebral ischemia-reperfusion injury by modulating tryptophan and tyrosine metabolism and activating NFE2L2/NRF2.
    Authors: Liu HX, Yang MK, Li YC, Liu CX, Li GP, Meng XL, Pei K, Wen SY
    Journal: International Journal of Phytotherapy and Phytopharmacology
    Year: 2025

 

  • Title: Astragalus injection inhibits the growth of osteosarcoma by activating cytotoxic T lymphocyte and targeting CTSL.
    Authors: Liu HX, Li YC, Su RB, Liu CX, Wen SY.
    Journal: Journal of Ethnopharmacology
    Year: 2025